Nexalin Technology, Inc. develops non-invasive neurostimulation products based on Deep Intracranial Frequency Stimulation, or DIFS™, for brain-health and mental-health indications. Company news commonly covers peer-reviewed clinical publications, neuroimaging and biomarker data, and research programs addressing insomnia, depression, traumatic brain injury, PTSD, Alzheimer’s disease, dementia-related cognitive decline and ADHD.
Updates also describe the HALO™ Clarity device, the NeuroCare® virtual clinic platform, collaborations with clinical research and academic organizations, FDA engagement, and capital-market communications tied to its Nasdaq-listed common stock.
Nexalin Technology (Nasdaq: NXL) has regained compliance with Nasdaq’s minimum bid price requirement and received permission for continued listing.
Its closing bid price remained above $1.00 per share for 21 consecutive trading days, from August 31 through September 29, 2026, following a previously announced reverse stock split. Nasdaq’s September 30 confirmation followed the Hearings Panel’s September 25 decision granting continued listing. Nexalin must still demonstrate compliance with the $2.5 million minimum stockholders’ equity requirement by January 4, 2027; continued listing remains conditional on the Panel’s terms.
Nexalin said it remains focused on commercial revenue generation following a distribution agreement covering Brazil and six additional South American markets, while advancing U.S. clinical programs, including its pivotal HALO Clarity insomnia trial, toward FDA marketing authorization.
Nexalin Technology (Nasdaq: NXL) signed a definitive exclusive distribution agreement with Inovanexa Medical Technologies covering seven South American countries.
The 10-year agreement covers Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela and supersedes the February 2026 letter of intent. It includes a binding initial order for 10 Nexalin Sync devices, five for immediate delivery, and a Brazilian clinical pilot targeted within 90 days. Sync has ANVISA approval in Brazil for anxiety, depression and insomnia.
A pricing framework covers the first 100 devices. After purchasing the first 30, Inovanexa must establish Brazilian manufacturing at its own cost. Nexalin receives fixed compensation per locally manufactured device placed in the market and royalties per locally manufactured disposable electrode sold. Exclusivity requires minimum revenue thresholds; renewals and manufacturing depend on distributor performance.
Nexalin Technology (NXL) appointed Robert DiTota senior strategic adviser for global commercialization, effective September 15, 2026.
DiTota will advise on distribution, market development and the infrastructure needed to support sales. Nexalin plans to begin in China, Brazil, Oman and Israel, where its Gen-2 SYNC 15 milliamp device is approved, and extend to the United States and Europe as regulatory milestones are achieved. In a randomized, double-blind, sham-controlled trial, the device showed improvement versus sham on the Mini-Mental State Examination (P = .001) and Montreal Cognitive Assessment (P = .03). Nexalin has also completed an FDA Q-Submission meeting in support of a planned U.S. Alzheimer’s pilot study; its HALO Clarity pivotal program in insomnia is ongoing.
Nexalin Technology (NXL) reported a new exploratory, item-level secondary analysis of Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog) data from its completed randomized, double-blind, sham-controlled trial of the 15 mA Gen-2 SYNC DIFS™ neurostimulation device in patients with mild Alzheimer’s disease.
The 46‑patient trial’s main results were previously published in the Journal of Alzheimer’s Disease (2024) and Radiology (2025). Among 20 active-arm participants with complete ADAS‑Cog data, 10 achieved an improvement of four or more points at one or more assessments, a threshold widely regarded as clinically meaningful. The largest individual gains, eight points each, occurred in the two most cognitively impaired patients at baseline. Domain‑level review found improvements at three‑month follow‑up in recognition memory, comprehension of spoken language, spoken language ability, word‑finding, and constructional praxis. The company emphasizes that this post‑hoc, descriptive analysis with a small sample and no adjustment for multiple comparisons is hypothesis‑generating and is intended to guide endpoint and patient‑selection strategy for a planned U.S. pilot study.
Nexalin Technology (Nasdaq: NXL) has approved a 1-for-30 reverse stock split of its common stock to help ensure continued compliance with the Nasdaq bid-price rule. Stockholders previously approved future reverse splits and authorized the board to set exact ratios and timing.
The reverse split becomes effective on August 28, 2026 at 5:00 p.m. ET, with trading on a split-adjusted basis on the Nasdaq Capital Market expected to begin on August 31, 2026 under the unchanged ticker NXL and new CUSIP 65345B300. Every 30 issued and outstanding shares will be combined into one share, while par value remains $0.001. No fractional shares will be issued; eligible holders will receive proportional cash payments. Continental Stock Transfer & Trust will act as exchange agent, and shareholders holding in book-entry or street name are not required to take action.
Nexalin Technology (Nasdaq:NXL) announced that Dr. Victor Fontenelle Bastos de Lima, an investigator in its Brazilian clinical trial, received the Young Researcher Award at BRAIN 2026 for work using Nexalin’s DIFS™ 15 mA, 77.5 Hz platform.
The single-center study in adults with generalized anxiety disorder and comorbid insomnia showed significant, durable improvement in sleep quality by PSQI. Nexalin holds ANVISA approval to market its Nexalin SYNC device for anxiety, depression, and insomnia in Brazil and is advancing its FDA De Novo pathway, including the HALO™ Clarity pivotal program.
Nexalin Technology (Nasdaq:NXL) announced that two clinical abstracts featuring its proprietary DIFS™ 15 mA, 77.5 Hz neuromodulation platform were accepted for presentation at the 2026 NYC Neuromodulation Conference.
Preliminary data show improvements in anxiety, depression, insomnia and quality of life, including a 77.8% anxiety response rate, 66.7% depression response/remission rates, durable 8-week benefits, and no serious adverse events, seizures or manic/hypomanic switches reported.
Nexalin Technology (Nasdaq:NXL) reported results from an 8-week, single-center, open-label clinical trial in Brazil using its DIFS™ 15 mA, 77.5 Hz device in adults with generalized anxiety disorder and insomnia.
The study showed a 77.8% anxiety response rate, 66.7% depression response/remission, sustained sleep and quality-of-life gains, and no serious adverse events, supporting Nexalin’s planned Brazilian product launch and broader clinical strategy.
Nexalin Technology (Nasdaq:NXL) received U.S. Patent No. 12,629,519 covering a transcranial alternating current dynamic frequency stimulation method for anxiety, depression and insomnia.
The patent is expected to protect Nexalin’s core method in the U.S. through 2042, supporting its HALO™ Clarity platform and Nexalin NeuroCare™ virtual clinic strategy in non-invasive deep-brain neurostimulation.
Nexalin Technology (Nasdaq:NXL) highlighted U.S. House Appropriations Committee report language directing the VA to support more research into non-invasive deep brain neurostimulation for treatment-resistant traumatic brain injury (TBI). The provision, advocated by Nexalin America, aligns with Nexalin’s UC San Diego/VA DIFS™ TBI study and could expand VA research opportunities.